Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
|Articles|October 27, 2011
- October 2011
- Volume 27
- Issue 1
Conference Calendar 2012
Advertisement
Articles in this issue
almost 15 years ago
Just Say No?almost 15 years ago
Effect of Marriage on Duration of Chest Pain Before Seeking Carealmost 15 years ago
Quality of Care and Outcome in Critical Access Rural HospitalsAdvertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Advertisement
Advertisement
Trending on HCPLive
1
No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH
2
ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years
3
FDA Accepts NDA for Zalunfiban in Prehospital STEMI Treatment
4
EADV Congress 2026: Day 2 Recap—6 Headlines to Know
5